A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders. Issue 6 (22nd November 2016)
- Record Type:
- Journal Article
- Title:
- A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders. Issue 6 (22nd November 2016)
- Main Title:
- A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders
- Authors:
- Sano, Hirozumi
Kobayashi, Ryoji
Suzuki, Daisuke
Hori, Daiki
Kishimoto, Kenji
Kobayashi, Kunihiko - Abstract:
- Abstract: Background: This randomized prospective study was designed to assess whether piperacillin/tazobactam (PIPC/TAZ) is as effective as meropenem (MEPM) as a first‐line antibiotic treatment for febrile neutropenia (FN). Procedure: FN episodes were randomly assigned to receive either PIPC/TAZ (337.5 mg/kg per day in three doses, 1‐hr DIV, maximum 13.5 g per day) or MEPM (120 mg/kg per day in three doses, 1‐hr DIV, maximum 3 g per day). Clinical responses were evaluated 120 hr after the DIV. Results: A total of 434 febrile episodes in 105 patients (42 females and 63 males) with a median age of 8 years (range 0–25) were included in this trial. Blood cultures were positive in 47 out of the 434 episodes (10.8%). Regarding responses to the treatment, success rates between the PIPC/TAZ and MEPM groups were similar (62.4 vs. 65.9%, P = 0.484), even if patients were restricted to those with bacteremia (26.1 vs 37.5%, P = 0.534). Mortality rates did not significantly differ between the two groups (0.8 vs. 0%, P = 0.500). Conclusion: Both PIPC/TAZ and MEPM appeared to be equally efficacious and safe. Carbapenems are now broadly used to treat FN; however, this may increase the prevalence of drug‐resistant bacteria. In this regard, the treatment using PIPC/TAZ for FN is more beneficial.
- Is Part Of:
- Pediatric blood & cancer. Volume 64:Issue 6(2017)
- Journal:
- Pediatric blood & cancer
- Issue:
- Volume 64:Issue 6(2017)
- Issue Display:
- Volume 64, Issue 6 (2017)
- Year:
- 2017
- Volume:
- 64
- Issue:
- 6
- Issue Sort Value:
- 2017-0064-0006-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2016-11-22
- Subjects:
- empirical therapy -- febrile neutropenia -- piperacillin/tazobactam -- meropenem
Tumors in children -- Periodicals
Blood -- Diseases -- Periodicals
Cancer in children -- Periodicals
618.92 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/pbc.26360 ↗
- Languages:
- English
- ISSNs:
- 1545-5009
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6417.533500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 1383.xml